Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

AstraZeneca Continues to Advance Early Lung Cancer Treatment and Redefine Metastatic Breast Cancer Care at ASCO 2024

NextEdge Admin

23 May 2024

2 min 41 sec

At the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, AstraZeneca is set to unveil a trove of groundbreaking data that underscores its commitment to revolutionizing cancer care. With over 100 abstracts, the event will spotlight 25 approved and potential new medicines across AstraZeneca’s expansive oncology portfolio and pipeline, including two late-breaking plenary presentations and 15 oral presentations.

Among the highlights is the LAURA Phase III trial showcasing Tagrisso’s efficacy in unresectable Stage III EGFRm NSCLC post chemoradiotherapy (CRT). Similarly, the ADRIATIC Phase III trial of Imfinzi in limited-stage small cell lung cancer (LS-SCLC) is poised to demonstrate significant progress. The DESTINY-Breast06 Phase III trial will reveal Enhertu’s potential in treating metastatic breast cancer, including HER2-low subtypes.

Exciting advancements also include the first-in-human trial of C-CAR031, a novel CAR-T therapy for liver cancer, and late-breaking presentations from the I-SPY2.2 Phase II trial, exploring novel combinations in breast cancer treatment.

Furthermore, AstraZeneca aims to redefine lung cancer treatment paradigms by presenting data from trials like ADAURA, AEGEAN, and COAST, focusing on early-stage and metastatic settings. Notably, efforts to extend the benefits of antibody drug conjugates (ADCs) in lung cancer treatment are emphasized.

In breast cancer, AstraZeneca continues to redefine treatment landscapes with ADCs across subtypes and disease stages. The DESTINY-Breast trials, including DESTINY-Breast06 and DESTINY-Breast03, showcase the efficacy of Enhertu, while TROPION-Breast01 explores the potential of datopotamab deruxtecan.

Advancing the next wave of medicines, AstraZeneca highlights promising data from trials like C-CAR031 for hepatocellular carcinoma and AZD0901 for gastric cancer. Collaboration with partners like Daiichi Sankyo and MSD underscores AstraZeneca’s commitment to driving innovation in cancer therapeutics.